We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Impact of High-density Lipoprotein Cholesterol (HDL-C) Levels and Risk of Movement Disorders in Patients Taking Antipsychotics.
- Authors
O'Donnell, Carolyn; Demler, Tammie Lee; Trigoboff, Eileen; Lee, Claudia
- Abstract
Introduction: Well-known adverse events of antipsychotics are movement disorders, or extrapyramidal symptoms, such as drug- induced parkinsonism and tardive dyskinesia. Objective: With new evidence suggesting a link between low high-density lipoprotein cholesterol (HDL-C) and risk of Parkinson's disease, this study sought to investigate if that link also translated to patients taking antipsychotics with low HDL-C and an increased risk for developing a movement disorder. Design: Adult patients (n=89) at an inpatient state psychiatric facility taking at least one antipsychotic with at least one HDL-C level were assessed for signs of a movement disorder through their history and physical, progress notes, and Abnormal Involuntary Movement Scale (AIMS) score. Results: There was no statistical significance when comparing a patient's movement disorder, AIMS scores, and HDL-C levels to suggest that the HDL-C level influenced a patient's movement disorder. Conclusion: This study did not show a correlation between HDL-C levels and a patient's risk of developing a movement disorder while taking an antipsychotic.
- Subjects
HDL cholesterol; RISK assessment; PSYCHOTHERAPY patients; T-test (Statistics); PARKINSON'S disease; ANTIPSYCHOTIC agents; MOVEMENT disorders; PSYCHIATRIC hospitals; PSYCHOSOCIAL factors; DISEASE risk factors
- Publication
Innovations in Clinical Neuroscience, 2024, Vol 21, Issue 4-6, p27
- ISSN
2158-8333
- Publication type
Article